Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a ...

The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also not clear that it wasn't. Until the medicine receives clearance from the U.S.

Iovance Biotherapeutics (NASDAQ: IOVA) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or ...

On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message ...

Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances ...

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance's full-year ...

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money. So does investing in most biotech stocks. But ...

Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation ...

SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and ...

The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. Certain matters discussed in this press release are ...